Firebrick Pharma (ASX:FRE) share price launches 165% following ASX IPO

The market has enthusiastically welcomed the pharmaceutical development firm.

| More on:
Vanadium Resources share price person riding rocket indicating share price increase

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Firebrick Pharma has debuted on the ASX – launching 125% on open to trade at 45 cents
  • The company is developing Nasodine Nasal Spray ­– designed to treat viruses such as the common cold
  • During its IPO, the company offered shares for 20 cents apiece

Virus-killing nasal spray developer, Firebrick Pharma Limited (ASX: FRE) saw its share price open 125% higher than its initial public offering's (IPO's) offer price upon its ASX float today.

The company's stock hit the market at 12:30 pm AEDT on Friday and quickly surged to a high of 53.5 cents.

At the time of writing, the Firebrick Pharma share price is 53 cents, 165% higher than its offer price.

For context, Firebrick Pharma's prospectus offered its shares for just 20 cents apiece.

Let's take a look at what the company does and all the details of its ASX IPO.

But first, what is Firebrick Pharma?

Firebrick Pharma is a pharmaceutical development firm focused on its patented Nasodine – a nasal spray designed to help treat viruses such as the common cold.

The product has been under development for nearly 10 years. It uses povidone-iodine (0.5%) as the active ingredient – the same active ingredient found in Betadine.

A quick fun fact: The name Firebrick is the hexadecimal colour of povidone-iodine.

Nasodine has undergone 3 human trials and Firebrick expects one more phase 3 clinical trial will be enough to see it approved as a treatment for the common cold in adults. That (potential) final trial will go ahead this year.

If all goes to plan, the product will then be sent to regulators for approval in Australia, the United Kingdom, and Europe.

The nasal spray is also expected to be put to the test against COVID-19 in a phase 2 clinical trial in 2022. The company hopes that the trial will show the product can reduce shedding of the COVID-19 virus.

Its co-founders and leaders, Dr Stephen Goodall and Dr Peter Molloy have previously been involved in the leadership of multiple ASX-listed biopharmaceutical companies.

Goodall is Firebrick's chief operating officer while Molloy is its chair.

Molloy also used to be responsible for the Betadine range in Australia, helped launch Betadine Sore Throat Gargle, and previously was CEO of Race Oncology Ltd (ASX: RAC).

What you need to know about Firebrick Pharma's ASX IPO

The ASX has warmly welcomed Firebrick Pharma following its IPO.

Under its prospectus, it sold 35 million shares for 20 cents apiece, raising $7 million. That saw its IPO offer fully subscribed. The funds will go towards ongoing clinical trials, marketing, and operating costs.

At its offer price, the company expected to list with a market capitalisation of around $33.8 million.

However, at its opening price, it had a valuation of approximately $76 million.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on IPOs

An arrow going upwards with a road sign saying 'IPO ahead'.

Should you buy into an IPO or wait until shares start trading on the ASX?

IPOs can be exciting, but also dangerous for investors.

Read more »

A female miner wearing a high vis vest and hard hard smiles and holds a clipboard while inspecting a mine site with a colleague.

ASX IPO alert: Blockbuster copper listing coming soon

Here's what you need to know about this upcoming IPO.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.

Fewer ASX IPOs in 2023, but here's how they've performed

We reveal the top 10 new listings by size and how their share prices have changed to date.

Read more »

IPO written in yellow and stuck in the air.
Materials Shares

Rich listers are buying into the IPO of ASX lithium explorer Kali Metals

There's a new lithium share in town. Here's what you need to know.

Read more »

IPO written in circles with a man holding a smartphone and a laptop open.
International Stock News

The highs and lows of the Instacart $11 billion IPO

Here is a closer look at the latest company to hit the Nasdaq exchange.

Read more »

Two businessmen shake hands against a tech backdrop, indicating a company IPO or a merger between two technology stocks.

This $85 billion company is about to start trading on the Nasdaq. Here's what you need to know

Arm is set to join the ranks of other AI high-flyers on the Nasdaq tonight.

Read more »

A businessman hugs his computer and smiles.
Materials Shares

The ASX welcomed a new lithium stock today, and it's up 50%!

Investors have been getting excited about this new lithium stock today.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Redox share price drops after IPO

One of the biggest IPOs in some time has taken place on the ASX today.

Read more »